Daiichi Sankyo at ESMO (Kyle LaHucik for Endpoints News)
October 20, 2023 05:05 AM EDTUpdated 11:17 AM
Deals

Mer­ck dou­bles down on AD­Cs with $4B up­front to Dai­ichi Sankyo, go­ing for ‘same in­ten­si­ty’ as megablock­buster Keytru­da

Amber Tong

Kyle LaHucik

Senior Reporter

MADRID — Mer­ck is com­mit­ting $4 bil­lion up­front to team up with Dai­ichi Sankyo on a trio of an­ti­body-drug con­ju­gates, adding fu­el to a space …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Sage re­ports Phase 2 fail­ure in Hunt­ing­ton's dis­ease, ends drug's de­vel­op­ment

Car­olyn Bertozzi’s lat­est biotech de­buts with $30M seed round and a sug­ary spin on im­munother­a­py

Pfiz­er taps on­col­o­gy head Boshoff as Dol­sten's chief sci­en­tif­ic of­fi­cer suc­ces­sor

Ex­clu­sive: For­mer Pfiz­er com­mer­cial chief An­gela Hwang to join Flag­ship

GSK plots reg­u­la­to­ry fil­ings for PBC itch af­ter pos­i­tive Phase 3 read­out

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times